Identification of a novel mechanism for reversal of doxorubicin-induced chemotherapy resistance by TXNIP in triple-negative breast cancer via promoting reactive oxygen-mediated DNA damage
Given that triple-negative breast cancer (TNBC) lacks specific receptors (estrogen and progesterone receptors and human epidermal growth factor receptor 2) and cannot be treated with endocrine therapy, chemotherapy has remained the mainstay of treatment. Drug resistance is reportedly the main obstac...
Main Authors: | Chen, Y. (Author), Feng, X. (Author), Jiang, J. (Author), Yuan, Y. (Author), Zhang, B. (Author), Zhang, P. (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer Nature
2022
|
Online Access: | View Fulltext in Publisher |
Similar Items
-
Optimizing doxorubicin-G-CSF chemotherapy regimens for the treatment of triple-negative breast cancer
by: Paredes Bonilla, Rosalba Vivian
Published: (2021) -
Folate-Functionalized DNA Origami for Targeted Delivery of Doxorubicin to Triple-Negative Breast Cancer
by: Suchetan Pal, et al.
Published: (2021-08-01) -
Cepharanthine sensitizes triple-negative breast cancer cells to doxorubicin and inhibits cell proliferation
by: ZHANG Yanhao, et al.
Published: (2019-11-01) -
Antitumor activity of Noscapine in combination with Doxorubicin in triple negative breast cancer.
by: Mahavir B Chougule, et al.
Published: (2011-03-01) -
CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy
by: Bray Denard, et al.
Published: (2018-08-01)